Catalyst Competitors
| CPRX Stock | USD 21.15 0.24 1.12% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Catalyst Pharmaceuticals competition on your existing holdings.
Catalyst |
Catalyst Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Catalyst Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Catalyst and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Catalyst Pharmaceuticals does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Catalyst Stock performing well and Catalyst Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Catalyst Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 2.12 | (0.16) | 0.00 | (0.08) | 0.00 | 3.84 | 11.44 | |||
| TERN | 3.35 | (0.50) | 0.00 | (0.32) | 0.00 | 5.68 | 34.09 | |||
| XFOR | 4.87 | (0.74) | 0.00 | (0.34) | 0.00 | 6.90 | 62.35 | |||
| INZY | 2.67 | (1.11) | 0.00 | (0.48) | 0.00 | 5.68 | 16.62 | |||
| MREO | 2.64 | (0.41) | 0.00 | (0.16) | 0.00 | 5.14 | 19.32 | |||
| EXEL | 1.42 | 0.39 | 0.25 | 0.93 | 0.97 | 3.14 | 14.75 | |||
| TGTX | 2.95 | 0.35 | 0.12 | 0.26 | 3.18 | 7.62 | 24.51 | |||
| VKTX | 3.49 | (0.37) | 0.00 | (0.16) | 0.00 | 6.24 | 34.61 | |||
| MDGL | 2.62 | 0.43 | 0.15 | 1.40 | 2.17 | 4.92 | 30.27 | |||
| BTAI | 4.44 | (0.36) | 0.00 | (0.04) | 0.00 | 9.62 | 39.77 |
Cross Equities Net Income Analysis
Compare Catalyst Pharmaceuticals and related stocks such as Day One Biopharmaceu, Terns Pharmaceuticals, and X4 Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (179.5 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (40.6 M) | (50.2 M) | (60.3 M) | (90.2 M) | (85.7 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (96.1 M) |
| INZY | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (18.6 M) | (55.8 M) | (56.4 M) | (65.4 M) | (71.2 M) | (74.7 M) |
| MREO | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (30.9 M) |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 218.2 M |
| TGTX | (3.6 M) | (853.1 K) | (18.1 M) | (20.5 M) | (55.8 M) | (62.9 M) | (78.3 M) | (118.5 M) | (173.5 M) | (179.3 M) | (285.9 M) | (355.6 M) | (203.8 M) | 12.7 M | 13.3 M |
| VKTX | (146.2 K) | (146.2 K) | (146.2 K) | (146.2 K) | (21.9 M) | (23.4 M) | (14.7 M) | (20.6 M) | (22.1 M) | (25.8 M) | (39.5 M) | (54 M) | (67.4 M) | (85.9 M) | (81.6 M) |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (68.7 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (299.3 M) | (373.6 M) | (354.9 M) |
| BTAI | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (636 K) | (2.1 M) | (4.5 M) | (19.3 M) | (32.3 M) | (82 M) | (106.6 M) | (171.8 M) | (179.1 M) | (170.1 M) |
| AXSM | (2.2 M) | (2.2 M) | (2.2 M) | (2.2 M) | (6 M) | (10.6 M) | (27.2 M) | (28.9 M) | (31 M) | (69.7 M) | (105.4 M) | (134.9 M) | (197.8 M) | (239.2 M) | (227.3 M) |
| INCY | (4.9 M) | (186.5 M) | (44.3 M) | (83.1 M) | (48.5 M) | 6.5 M | 104.2 M | (313.1 M) | 109.5 M | 446.9 M | (295.7 M) | 948.6 M | 340.7 M | 597.6 M | 627.5 M |
| SRPT | (2.6 M) | (2.3 M) | (121.3 M) | (112 M) | (135.8 M) | (220 M) | (267.3 M) | (50.7 M) | (361.9 M) | (715.1 M) | (554.1 M) | (418.8 M) | (703.5 M) | (536 M) | (509.2 M) |
| ACAD | (10.2 M) | (22.8 M) | (20.8 M) | (37.9 M) | (92.5 M) | (164.4 M) | (271.4 M) | (289.4 M) | (245.2 M) | (235.3 M) | (281.6 M) | (167.9 M) | (216 M) | (61.3 M) | (64.4 M) |
| HEPA | (843 K) | (843 K) | (843 K) | (5.3 M) | (5.3 M) | (14.3 M) | (17 M) | (14.9 M) | (9.4 M) | (7 M) | (20.4 M) | (32.7 M) | (42.2 M) | (48.9 M) | (46.5 M) |
| AKRO | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (81.7 M) | (43.8 M) | (79.2 M) | (100.7 M) | (108.9 M) | (151.8 M) | (144.2 M) |
Catalyst Pharmaceuticals and related stocks such as Day One Biopharmaceu, Terns Pharmaceuticals, and X4 Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Catalyst Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Catalyst Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Catalyst Pharmaceuticals Competitive Analysis
The better you understand Catalyst Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Catalyst Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Catalyst Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Catalyst Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of Catalyst Pharmaceuticals Competition
Catalyst Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Catalyst Pharmaceuticals in relation to its competition. Catalyst Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Catalyst Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Catalyst Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Catalyst Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Catalyst Pharmaceuticals position
In addition to having Catalyst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Conservative Funds Thematic Idea Now
Conservative Funds
Funds or Etfs that invest using buy-and-hold investment strategy in companies with consistent growth over many years of operation. The Conservative Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Conservative Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.